My Portfolio

Rigel Pharmaceuticals Inc RIGL:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 4:03 PM EDT

30.86

+0.56 (+1.85%)

Volume

5,572

30.30

+0.28 (+0.93%)

Volume

416,349

52 week range

18.14 - 52.24

Open29.93
Day High30.41
Day Low29.57
Prev Close30.02
52 Week High52.24
52 Week High Date11/28/25
52 Week Low18.14
52 Week Low Date06/25/25

Latest On Rigel Pharmaceuticals Inc

Lightning Round: Sell Penn EntertainmentMarch 25, 2026CNBC.com
Here are the 5 big things we're watching in the stock market this weekMarch 1, 2026CNBC.com
This biotech stock has jumped 50% in 3 months October 30, 2025CNBC.com
Rigel Pharmaceuticals CEO Raul Rodriguez on profitability and product growthOctober 30, 2025CNBC.com

Key Stats

Market Cap560.614M
Shares Out18.50M
10 Day Average Volume0.33M
Dividend-
Dividend Yield-
Beta1.18

Latest On Rigel Pharmaceuticals Inc

Lightning Round: Sell Penn EntertainmentMarch 25, 2026CNBC.com
Here are the 5 big things we're watching in the stock market this weekMarch 1, 2026CNBC.com
This biotech stock has jumped 50% in 3 months October 30, 2025CNBC.com
Rigel Pharmaceuticals CEO Raul Rodriguez on profitability and product growthOctober 30, 2025CNBC.com

KEY STATS

Open29.93
Day High30.41
Day Low29.57
Prev Close30.02
52 Week High52.24
52 Week High Date11/28/25
52 Week Low18.14
52 Week Low Date06/25/25
Market Cap560.614M
Shares Out18.50M
10 Day Average Volume0.33M
Dividend-
Dividend Yield-
Beta1.18

RATIOS/PROFITABILITY

EPS (TTM)18.43
P/E (TTM)1.64
Fwd P/E (NTM)7.78
EBITDA (TTM)126.986M
ROE (TTM)174.08%
Revenue (TTM)299.767M
Gross Margin (TTM)93.39%
Net Margin (TTM)121.51%
Debt To Equity (MRQ)11.22%

EVENTS

Earnings Date08/03/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Rigel partner Kissei submits new drug application for olutasidenib in JapanMay 27, 2026TipRanks
H.C. Wainwright highlights Rezlidhia NDA as expanding Rigel’s ex-U.S. reachMay 27, 2026TipRanks
Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches CompletionMay 22, 2026TipRanks
Rigel Shareholders Approve Equity Plans and Board SlateMay 20, 2026TipRanks
Rigel Pharmaceuticals Highlights Growth Amid Rising CostsMay 19, 2026TipRanks

Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the...

Gregg Lapointe CPA

Independent Chairman of the Board

Raul Rodriguez

President, Chief Executive Officer, Director

Dean Schorno CPA

Chief Financial Officer, Executive Vice President

Raymond Furey

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Lisa Rojkjaer M.D.

Executive Vice President, Chief Medical Officer

Address

611 GATEWAY BOULEVARD, SUITE 900

South San Francisco, CA

94080

United States

https://www.rigel.com/